Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Invested Capital (2020 - 2025)

Nurix Therapeutics (NRIX) has disclosed Return on Invested Capital for 4 consecutive years, with 0.63% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Invested Capital fell 16.0% to 0.63% in Q4 2025 year-over-year; TTM through Nov 2025 was 0.63%, a 16.0% decrease, with the full-year FY2025 number at 0.54%, up 5.0% from a year prior.
  • Return on Invested Capital was 0.63% for Q4 2025 at Nurix Therapeutics, up from 0.65% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.26% in Q3 2021 to a low of 0.85% in Q1 2024.
  • A 4-year average of 0.49% and a median of 0.5% in 2025 define the central range for Return on Invested Capital.
  • Peak YoY movement for Return on Invested Capital: tumbled -31bps in 2022, then surged 39bps in 2025.
  • Nurix Therapeutics' Return on Invested Capital stood at 0.33% in 2021, then crashed by -73bps to 0.57% in 2022, then increased by 17bps to 0.47% in 2024, then tumbled by -33bps to 0.63% in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Return on Invested Capital are 0.63% (Q4 2025), 0.65% (Q3 2025), and 0.5% (Q2 2025).